LAUREANO SIMON, Oncomatryx CEO, declares war on tumor microenvironment. “We envision a new era where cancer in general and invasive tumors in particular will be beaten with orchestrated combinations of precision
“I declare war on cancer stroma”

LAUREANO SIMON, Oncomatryx CEO, declares war on tumor microenvironment. “We envision a new era where cancer in general and invasive tumors in particular will be beaten with orchestrated combinations of precision
ESMO 2018 Congress Munich, Germany – 19 Oct – 23 Oct 2018 Myriam Fabre, PhD. (Oncomatryx R&D Director) presents the poster: OMTX705, a powerful stroma-targeting ADC to treat invasive tumors with
Oncomatryx will attend BIO EUROPE SPRING 2018, the essential appointment in biotechnology BIO EUROPE SPRING 2018 March 12-14, 2018 Amsterdam, The Netherlands https://ebdgroup.knect365.com/bioeurope- If you are also attending this event and you would like
Oncomatryx will attend BIO 2017, the Global Event for Biotechnology.
ENTURE SUMMIT WEST 2017 February 28 – March 1 2017 Mountain View, CA USA David Raksin, our Business Development Director will be a Presenting role as a Top Innovator in
Antibody Drug Conjugates Against Tumor Stroma: The Beginning of The End? by Mirella Zulueta, Business Development Director at Oncomatryx The potential of a technology trigger Despite many research breakthroughs
Oncomatryx will attend BIOEUROPE. November 7-9. Cologne. FOCUS. November 9-12. Cyprus. If you are also attending any of these events and you would like to meet us please fill
Oncomatryx at the “Cancer Metabolism and the Tumour Microenvironment Conference”. 9-12, November. Paphos, Cyprus. Myriam Fabre, PhD. (Oncomatryx R&D Director) will attend the conference as speaker: TARGETING TUMOR MICROENVIRONMENT TO
Poster presentation at the 2nd ASPIC International Congress. 28-29 April, 2016. Porto. Portugal. We are pleased to inform you that Enrique De Alava team from Hospital Virgen del Rocío, Sevilla, Spain,